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Abstract
Donor cell leukaemia (DCL) is a rare complication of allogeneic haematopoietic cell transplantation (HCT). We have
investigated the prevalence and outcome of donor cell haematology malignancies within centres registered with the
European Society of Blood and Marrow transplantation (EBMT). We have sought to identify risk factors to shed light on the
pathogenesis of DCL as a model for leukaemogenesis. DCL cases were identified by questionnaire and a follow-up
questionnaire requested detailed data. Control subjects from the EBMT registry who had not developed DCL were used for a
matched pair analysis to identify risk factors. We identified 38 patients with DCL; the estimated prevalence was 80.5/
100,000 transplants. Patients were predominantly treated for haematological malignancy. A clone was retrospectively
identified in 7/25 (28%) donors for whom data was available. Overall survival was poor with 29/38 patients dead a median
of 11 (range 0–91) months after DCL diagnosis. Matched case-pair analysis identified three factors on multivariate analysis
as significantly associated with an increased risk for DCL: use of growth factors within the first 100 days after
transplantation, in vivo T-cell depletion and multiple allografts. The risk factors identified, support reduced immune
surveillance and replicative stress as pathogenic in the development of DCL.
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Second malignancies are well described in survivors of
allogeneic haematopoietic cell transplantation (HCT) and
include solid cancers, post-transplant lymphoproliferative
disease (PTLD) and donor related malignancies [1]. The
development of leukaemia or myelodysplasia in donor cells
within the recipient—‘donor cell leukaemia’ (DCL)—is rare
but well described. The first published case of DCL in 1971
reported a 16-year old girl, transplanted for refractory ALL
from her HLA (human leucocyte antigen) identical brother
[2]. Leukaemia recurred 62 days after marrow transplanta-
tion with blasts showing a male genotype. Since then, sev-
eral cases reports of DCL have been reported [2–11] and
also some small case series [12–15]. Increased reporting in
the last decade likely reflects the increasing number of HCT
performed but also improved ability to identify donor cell
origin. In 2005, the European Society for Blood and Marrow
Transplantation (EBMT) initiated a retrospective survey
collecting 14 cases of DCL from 91 centres reporting 10,489
transplants [12]. The incidence was estimated at 124 cases of
DCL per 100,000 transplantations during the time period
1982–2003. DCL was diagnosed a median of 17 months
after transplantation with no overt evidence of haematolo-
gical malignancy in the donor with a median follow-up of 9
years. In 2006, Sala-Torra et al. [14] reported 12 cases of
DCL [14]. In six of these, (pre-) malignant clones were
retrospectively detected within the donor after transplanta-
tion had taken place. These authors proposed categorising of
DCL into two groups: (1) a group in which a malignant
clone is inadvertently transferred to the donor at the time of
transplant and (2) a group in which donor cells become
malignant in the new host environment. Since monoclonal
lymphocytosis and lymphoid neoplasms increase with age,
the risk of accidental transferred DCL might be expected to
increase with increasing donor age [5, 16–19].
An alternative possibility is that undetected potential
malignant clones are transferred from donor to patient and
that these clones behave differently in the new host (transplant
patient) environment compared to the donor from which they
have come. Next generation sequencing has shed some light
on the behaviour of pre-leukaemic clones transferred from
donor in the context of allogeneic HCT. Berger et al. [20]
describe a DDX41 kindred in which siblings shared hetero-
zygous germline mutations in DDX41 and FANCD2.
Development of post-transplant DCL in the patient trans-
planted for AML/MDS from an unaffected brother was
accompanied by an expanding TET2 and TP53 clone from
the unaffected brother associated with some additional
mutations in DNMT3A and ASXL1 genes. Meanwhile the
brother who donated the TET2/TP53 clone remained free
from leukaemia highlighting the role of the environment in
leukaemic development. Herold et al. [21] described a case of
donor cell AML occurring 7 years after transplant for CLL,
with AML occurring in the donor at a similar time. They used
whole-exomic sequencing to chart the evolution of a donor
cell demonstrating clonal haematopoiesis of indeterminate
potential [22] in both the transplanted environment and in the
original host. Although both patient and donor developed
AML, different clones were demonstrated in each and the
clinical outcome was different for each patient.
Different pathogenic risk factors in the host have been
postulated to be relevant to the development of DCL [23,
24]. Replicative stress and telomere shortening resulting in
premature senescence, as well as cell cycle dysregulation
and epigenetic reprogramming due to the high number of
required cell divisions during HCT have been implicated.
Furthermore, impaired immune surveillance by immunor-
egulatory dysfunction and immunosuppression may con-
tribute. Viral reactivation is relevant to this as it can modify
immune reconstitution after HCT. The importance of the
stroma in supporting normal haematopoietsis is highlighted
by experiments in mice where genetically altered men-
senchymal osteoprogenitor cells are associated with the
development of MDS/leukaemia [25]. Damaged marrow
stroma and defective microenvironment and oncogenic
transformation can be exacerbated by antigenic or viral
stimulation. Another possible risk factor is use of exogen-
ous GCSF, which could enhance leukaemic transformation
through actions mediated via the GCSF receptor [26].
Due to the rarity of DCL very little is known about its
clinical risk factors, outcome and optimal management. We
have, therefore, updated a previous EBMT investigation of
DCL with a view to identifying potential risk factors for its
development and to evaluate outcome.
Methods
This was a multicentre cohort study. A questionnaire was sent
to all 305 EBMT centres actively reporting to the EBMT on
allogeneic transplant recipients. The EBMT is a voluntary
working group of transplant centres that are required to report
all consecutive stem cell transplantations and follow-ups once
a year. All patients provide informed consent authorising the
use of their personal information for research purposes and
the study was conducted in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines.
The questionnaire asked for reports of proven cases of
DCL. A follow-up questionnaire requested data on initial
disease, treatment, graft-versus-host disease (GvHD), immu-
nosuppression and infectious complications. In addition
details were sought regarding how donor cell origin was
determined, the subsequent treatment and outcome for
both patient and donor. Cumulative incidence of DCL was
estimated from the date of the last HCT before DCL, taking
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into consideration the competing risk of death due to other
causes.
Controls who had not developed DCL were collected from
the EBMT registry database and used in a nested case–control
(two controls for one case) analysis to identify prognostic
factors. Controls were matched for the following factors: age at
HCT(+ /- 5 years), gender, diagnosis (malignant vs. non
malignant), disease status at transplantation, year of transplan-
tation (+ /- 5 years), type of donor (HLA-identical
sibling, unrelated, haploidentical transplant), stem cell source
(BM, PB or CB) and duration of follow-up (see Table 1). In
one case it was not possible to get two controls and a single
control only was used. It was not possible to identify a control
for four of our DCL patients with the following diagnoses:
Fanconi anaemia, sickle cell disease, ALL and aplastic
anaemia.
Controls had a length of follow-up at least equal to the
time from last HCT to DCL. The following parameters were
investigated by univariate and multivariate analysis: donor
age, previous type of transplantation (autologous/allo-
geneic), reduced-intensity conditioning regimen (RIC), total
body irradiation (TBI ≥ 4 Gy), patient and donor CMV
serology, use of G-CSF within 100 days post-transplant,
in vivo T-cell depletion by anti-thymocyte globulin
(ATG) or alemtuzumab and occurrence of acute or chronic
GvHD.
Statistics
The two groups (cases and controls) were compared using
Chi-square for categorical variables and Mann–Whitney test
for continuous parameters. Multivariate analysis was per-
formed using a conditional logistic regression. Then a
stepwise backward and forward procedure was used with a
cutoff significance level of 0.05 for deleting factors in the
model. All p-values are two-sided with type I error rate
fixed at 0.05. Statistical analyses were performed with
SPSS 22 (SPSS Inc./IBM, Armonk, NY) and R 3.0.1
(R Development Core Team, Vienna, Austria) software
packages.
Results
Prevalence and cumulative incidence of DCL
Of 305 EBMT centres, 80 participated in this study (26.2%)
including data on 46,051 allogeneic transplants. Twenty-
eight of 80 centres (35%) reported a total of 38 DCL
patients. This gives an estimated DCL prevalence of 80.5
cases per 100,000 transplants and a cumulative incidence of
DCL at 5, 10, and 25 years after the last HCT of 0.067%,
0.132% and 0.363%, respectively.
Patient characteristics
Characteristics of patients affected by DCL and their con-
trols are summarised in Table 2. The majority were trans-
planted for underlying malignant disease. Twenty-four
patients (63%) had related (matched sibling n= 22, hap-
loidentical n= 2) donors and in 14 cases (37%) the donor
was unrelated. Most patients (37/38) received treatment
prior to the HCT preceding DCL diagnosis: 26/38 patients
received chemotherapy, in combination with immuno-
(3/26) or radiotherapy (6/26). One patient received immu-
notherapy only. Ten in 38 patients were heavily pretreated;
five patients underwent high-dose chemotherapy and auto-
logous transplantation and five patients received one (n= 4)
or two (n= 1) previous allogeneic HCT (three of them with
Table 1 Characteristics of patients and their matched control subjects
Controls DCL patients
Controls DCL patients










Gender Male 36 (54%) 18 (53%)
Female 31 (46%) 16 (47%)
Type of donor Sibling 41 (61%) 21 (62%)
Unrelated 24 (36%) 12 (35%)
Haploidentical 2 (3%) 1
Status at HCT CR 46 (69%) 23 (68%)
No CR 19 (28%) 10 (29%)
n/a 2 (3%) 1 (3%)
Source of stem
cells
BM 27 (40%) 14 (41%)
PB 36 (54%) 18 (53%)
CB 4 (6%) 2 (6%)
Diagnosis AML 23 (34%) 10 (29%)
ALL 10 (15%) 4 (12%)
CML 12 (18%) 8 (24%)
CLL 3 (4%) 3 (9%)
MDS 6 (9%) 4 (12%)
NHL 7 (10%) 3 (9%)
MM 4 (6%) 1 (3%)
SAA 2 (3%) 1 (3%)
33/38 patients had two matched controls and one additional patient had
a single matched control
DCL donor cell leukaemia, HCT haematopoietic cell transplantation,
CR complete remission, n/a non-applicable because diagnosis was
aplastic anaemia, BM bone marrow, PB peripheral blood, CB cord
blood, AML acute myeloid leukaemia, ALL acute lymphoid leukaemia,
CML chronic myeloid leukaemia, CLL chronic lymphocytic leukae-
mia, MDS myelodysplasia, NHS NHL non Hodgkins lymphoma, MM
multiple myeloma, SAA severe aplastic anaemia
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different donors and for two this information is not known).
Disease status prior to last HCT before DCL diagnosis was
available for 36/38 patients (Table 1). Conditioning regi-
mens were intended to be myeloablative in 26/38 patients
and 17/38 patients received TBI with a total dose of ≥ 8 Gy
(13/17) or ≤ 4 Gy (4/17). Sixteen in 34 cases (47%) received
GCSF in the first 100 days and 9/34 cases (26%) received
ATG. Acute GvHD was observed in 20/37 patients and
chronic GvHD in 17/38 patients: 10/17 with mild symptoms
and 7/17 with moderate or severe symptoms according to
the NIH classification [27].
Cytomegalovirus (CMV) reactivation within the first
100 days after transplantation was reported for 15/38
patients and over day+ 100 for 13/38 patients. Details of
reactivation of other viral pathogens are given in Table 2.
DCL diagnosis and demonstration of donor cell
origin/chimaerism analysis
Median time from last allogeneic transplantation to DCL
diagnosis was 44 months (range, 2–279 months). Donor cell
leukaemia was diagnosed as AML (N= 22) in 58% of the
cases, MDS (N= 7), ALL (N= 2), CML (N= 2) and CLL
(N= 5). Information on cytogenetic and molecular analyses
were available for 32/38 patients and 29/38 patients,
respectively. Aberrations included monosomy 7 in 5
patients (3 AML; 1 MDS; 1 CML), trisomy 8 in 3 patients
(2 AML; 1 MDS), RUNX1 mutation in two patients (two
AML), WT1 mutation in two patients (one MDS, one
AML) and immunoglobulin gene rearrangements in two
patients (CLL). Donor origin of disease was confirmed by
cytogenetics (FISH and/or conventional cytogenetics) in 11
patients, by molecular testing (STR/VNTR and/or HLA
typing) in 20 patients and by both techniques in six patients;
in one patient the method of donor type confirmation
remains unclear. Donor chimaerism was indicated as full
(33/38) or mixed (3/38; two conventional cytogenetics, one
STR/VNTR analysis) at the point of DCL diagnosis; for two
patients there were no detailed data available on the results
of chimaerism analysis (performed by HLA typing and
conventional cytogenetics).
DCL outcome and treatment
Treatment depended on the nature of the disease (Table 3).
Four did not receive further treatment (three CLL, one
MDS). Fourteen of 38 patients received conventional che-
motherapy and 18/38 were re-treated with HCT. 14/18
received a transplant from a new donor and two from the
same geno-identical donor. Three patients receiving HCT
for AML also received donor lymphocyte infusions (DLI)
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Overall survival following DCL was poor with 29/38
patients dead at a median time of 11 months after diagnosis
(range, 0–91 months). The main causes of death were relapse/
progression of DCL (12 patients), relapse/progression of pri-
mary disease (3 patients), transplant related causes of death
(10 patients), secondary malignancy (n= 1), sepsis (n= 1),
myocardial infarction (n= 1) and 1 patient unknown.
Of 9/38 patients remaining alive (median follow-up
63 months, range 32–196), four had chronic leukaemia
(three CLL, one CML), four had AML in CR (three
receiving HCT, one treated with chemotherapy) and one
had MDS (treated with HCT).
Donors’ characteristics and donor follow-up
The median donor age at HCT was 38 years [0–72]; 25/38
donors were male. Prior to HCT, all passed the standard
pre-HCT laboratory evaluation and had no clinical evidence
of disease. Follow-up data was available for 25/38 donors
(22 related and three unrelated donors). At the time of data
collection, all donors were alive a median of 6 years (range
1.6–26 years) post donation of their stem cells.
Detailed follow-up data was available for 25 donors; of
these seven developed overt evidence of haematological
malignancy during the follow-up time of this study (median
52 months, range 3.5–117). Five donors (HLA-identical
siblings) developed the same chronic leukaemia as their
recipient (four CLL, one CML). The donor/recipient pair
who developed CML were both diagnosed at a similar time
point 4 months after transplant. Where the donor had CLL
the time course of the recipient developing CLL varied from
1.4–9.1 years. A malignant clone was identified retro-
spectively within the graft in two donors [18].
Two donors (HLA-identical siblings) developed AML
4.4 and 9.8 years after donating stem cells; their recipients
developed MDS with a similar time course.
Case–control study/pathogenetic risk factor analysis
Thirty-four DCL cases were matched with 67 controls
(Table 4). In univariate analysis, the following factors were
identified as being significantly associated with an increased
risk for development of DCL (p < 0.05): the use of growth
factor within the first 100 days after transplantation (p=
0.015), and previous allograft (p= 0.01). By multivariate
analysis, three factors were significantly associated with a
higher risk of DCL: the use of growth factor within the first
100 days after transplantation (HR= 2.43; 95% CI:
1.15–5.13; p= 0.020), in vivo T-cell depletion by either
alemtuzumab or ATG (HR 2.59; 95% CI: 1.21–5.56; p=
0.014) and previous allograft (HR 4.08; 95% CI: 1.37–
12.19; p= 0.012). There was no significant association
between acute or chronic GvHD with DCL.
Discussion
This European multi-centre survey has characterised a series
of 38 DCL patients, which demonstrates the heterogeneity
of this rare complication. The estimated prevalence from
our data is 80.5 cases per 100.000 transplants. This is of
similar magnitude albeit lower than the 124 cases/100,000
transplants reported by the first EBMT centre survey on
DCL [12]. Other case series of DCL found a distinctly
higher prevalence with 4 cases/841 transplants [15] and up
to 2 cases/40 transplants [11]. For all studies, including the
present study, we cannot exclude under-reporting (no sys-
tematic search for DCL) or over-reporting because of lack
of involvement of centres without cases of DCL. Despite
the improvement in molecular diagnostic tools for detection
of donor type malignant cells, the frequency of cases
between 1985 and 2011 has not changed substantially from
the 20-year period 1982–2002 [12]. The median time
interval from HCT to DCL diagnosis reported in our study
is similar to that observed by Sala-Torra et al. [14].
Our data lends some support to the categorisation of DCL
into two different groups as already proposed [14] because in
some of our cases it was possible to demonstrate accidental
transfer of pre-existing malignant clones, whereas in others it
was not. However, it is recognised that leukaemia is a mul-
tistep process and although 7/28 donors had evidence of an
abnormal clone/disease, we cannot exclude the possibility that
additional donors had pre-leukaemic clones despite not
developing overt disease within the time frame of the study.
This is statistically more likely in donors who already had
family members with leukaemia (sibling transplants) but
could also apply to unrelated donors. It is also possible that
different mechanisms are relevant depending on whether the
patient developed a chronic or acute leukaemia.








Donor age >35 43 (64%) 18 (64%) 0.97
Previous auto HCT Yes 5 (7%) 4 (12%) 0.48
Previous allo HCT Yes 0 4 (12%) 0.01
Reduced-intensity HCT Yes 26 (39%) 12 (35%) 0.73
TBI Yes 41 (61%) 16 (47%) 0.18
Growth factor < 100 days Yes 17 (25%) 16 (50%) 0.015
in vivo T-cell depletion Yes 20 (30%) 14 (41%) 0.26
Acute GvHD grade II+ Yes 16 (24%) 10 (30%) 0.49
Chronic GvHD Yes 36 (59%) 17 (50%) 0.40
Alemtuzumab Yes 5 (7%) 5 (15%) 0.25
Anti-thymocyte globulins Yes 15 (22%) 9 (26%) 0.65
HCT haematopoietic cell transplant, GvHD graft-versus- host disease,
TBI total body irradiation
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In spite of modern techniques in molecular diagnostics, it
remains a challenge to confirm beyond doubt the donor
origin of malignant cells in DCL. Different methods for
analysing chimaerism are available, and while results of
cytogenetic analysis might be impaired by slowly dividing
leukaemic clones or missing spontaneous cell division,
further details like genomic instability with potential gain
and loss of the Y chromosome or clonal evolution still have
to be noted for FISH analysis [28]. The gold standard for
chimaerism analysis especially for verification of DCL are
STR- and VNTR analysis [29, 30]. The prerequisite is that
the collected material belongs to the malignant cell popu-
lation only. Nonetheless FISH analysis remains an accepted
technique to assess chimaerism in sex-mismatched trans-
plantations [24]. Recent use of whole-exome sequencing to
demonstrate emergence of AML in donor cells after allo-
geneic HCT also highlights the value of this technique in
demonstrating the donor origin of a leukaemic clone [20].
Cytogenetic abnormalities including monosomy 7 and
trisomy 8 were relatively frequent in patients developing
AML/MDS. Both are known to be associated with therapy-
related MDS and leukaemia after treatment with alkylating
agents. Several case reports also demonstrate the occurrence
of monosomy 7 and trisomy 8 in DCL [10, 15, 31]. In our
cohort 36/38 patients received an alkylating agent-
containing conditioning regimen. As these agents are
given sufficiently far ahead to avoid toxicity to incoming
cells, detection of therapy-associated chromosomal aberra-
tions implicates residual effects of the previous che-
motherapy on marrow stroma rather than a direct effect on
donor stem cells. The suggestion of a (pre-) damaged or
mutagenic microenvironment is further supported by a DCL
case after transplantation for Fanconi anaemia, a condition
in which the stroma is known to be defective [6, 32].
Two aims of the study were to identify potential risk fac-
tors for DCL and shed light on the pathogenesis of DCL as a
model for leukaemogenesis. Three factors were identified as
being significantly associated with an increased risk for DCL
development on multivariate analysis: the use of growth
factors within the first 100 days after transplantation, in vivo
T-cell depletion and multiple allografts. Telomere shortening
and replicative stress play a pivotal role in cell senescence
induced genomic instability as characterised in AML [30].
Significant telomere shortening has been observed in reci-
pients after HCT especially during the first year after trans-
plantation. Application of growth factors during the first
100 days after transplantation might further enhance replica-
tive stress leading to greater genomic instability and thereby
contributing to malignant transformation.
Expansion of a malignant clone is usually prevented by
functional immune surveillance mediated by cytotoxic
T-lymphocytes. Despite the existence of donor T-cells,
however, immune function remains impaired immediately
post transplant not least because of the immunosuppressive
agents administered to prevent graft failure and GvHD. In
our patient cohort, in vivo T-cell depletion was found to be
significantly associated with DCL development supporting
the hypothesis of impaired immune surveillance by reduced
functional T-lymphocytes.
In this analysis, prior allogeneic transplantation was
associated with an increased risk of developing DCL while
prior autologous transplantation was not. One could argue
that this lends support to the relevance of reduced immune
surveillance in DCL development.
Prognosis of DCL was poor and most of the patients died
of progression or relapse of the DCL. Transplantation-related
death was common. Nonetheless, in addition to three cases of
donor cell-derived chronic leukaemias, long-term survival
was also reported for five cases of MDS/AML, four of whom
underwent a second HCT from an alternative donor.
Summary and conclusion
In summary the data presented in this paper, representing
the largest series to date of patients developing DCL,
demonstrates that the outlook of DCL is poor. The
risk factor analysis supports reduced immune surveillance
and replicative stress as pathogenic in the development
of DCL.
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